Melanotan II (MT-II) acts primarily as a non-selective agonist of melanocortin receptors, particularly melanocortin receptor 3 (MC3R) and melanocortin receptor 4 (MC4R), influencing various biological processes such as skin pigmentation and appetite regulation. The activation of these receptors triggers downstream signaling pathways, including the cAMP/PKA pathway, which mediates effects on melanogenesis and appetite suppression. While the precise mechanisms underlying all of its effects, particularly in relation to renal injury and oxytocin modulation, are not fully understood, MT-II is known to impact neuroendocrine functions and may induce adverse renal effects through thrombotic influences and direct toxicity.